Kailera Therapeutics Inc. Common Stock (KLRA)
Stock · NASDAQ · Health Care
$11.24as of 10/16/2026
Price chart
Active signals
High Beta66.0%
Resistance level
$20.79
Industry
Biotechnology: Pharmaceutical Preparations
About KLRA
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 145
- Website
- www.kailera.com
Fundamentals
- 1-day range
- $10.5$11.76
- Market cap
- $2.44B
- P/E (trailing)
- —
- P/E (forward)
- -2.73
- EPS (trailing)
- $-2.25
- Dividend yield
- —
- Beta
- 2.45
- Avg. volume
- 934.0K
52-week range
$9.76$28.23
Next earnings: November 4, 2026 · EPS estimate $-1.01confirmed
Forecasts
5 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$57
+407.1%
Median
$41
+264.8%
Low
$30
+166.9%
Kailera Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KLRAKailera Therapeutics Inc. Common Stock$11.25▼ 3.93%Market cap $2.44BP/E —$9.76$28.23
- PGENPrecigen Inc. Common Stock$6.39▼ 11.25%Market cap $2.47BP/E —$3.04$8.98
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
- PHVSPharvaris N.V. Ordinary Shares$27.74▼ 6.41%Market cap $2.40BP/E —$20.65$43.25
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- ZLABZai Lab Limited American Depositary Shares$23.19▼ 1.36%Market cap $2.35BP/E —$12.31$26.6
- VRDNViridian Therapeutics Inc. Common Stock$19.03▼ 2.71%Market cap $2.32BP/E —$13.18$34.29
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KLRA Kailera Therapeutics Inc. Common Stock | $2.44B | — | $11.25 | ▼ 3.93% | $9.76$28.23 |
| PGEN Precigen Inc. Common Stock | $2.47B | — | $6.39 | ▼ 11.25% | $3.04$8.98 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
| PHVS Pharvaris N.V. Ordinary Shares | $2.40B | — | $27.74 | ▼ 6.41% | $20.65$43.25 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| ZLAB Zai Lab Limited American Depositary Shares | $2.35B | — | $23.19 | ▼ 1.36% | $12.31$26.6 |
| VRDN Viridian Therapeutics Inc. Common Stock | $2.32B | — | $19.03 | ▼ 2.71% | $13.18$34.29 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- GLP-1s: Still Early In The Growth StorySeekingAlpha · 10/2/2026
- Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual MeetingYahoo · 10/1/2026
- Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to BuyYahoo · 9/30/2026
- Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat ObesityYahoo · 9/30/2026
- Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide InjectionYahoo · 9/30/2026
- Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028Benzinga · 9/30/2026
- Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss DifferentiationSeekingAlpha · 9/18/2026
- Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug ApprovalSeekingAlpha · 9/17/2026
Insider Activity
Insider Actions →Acquired
22.72M
Disposed
15.95M
- Nicholson Nur · September 7, 2026 · Grant220.0K
- Tregoning Kathleen · July 6, 2026 · Grant175.0K
- Ronald C. Renaud Jr. · June 9, 2026 · Option Exercise38.1K @ $5.25
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion708.8K
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion4.97M
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion2.03M
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. · April 20, 2026 · Conversion9.48M
- RTW INVESTMENTS, LP · April 20, 2026 · Conversion2.03M
- RTW INVESTMENTS, LP · April 20, 2026 · Conversion8.25M
- RTW INVESTMENTS, LP · April 20, 2026 · Buy500.0K @ $16
- RTW INVESTMENTS, LP · April 20, 2026 · Conversion10.28M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Kailera Therapeutics faces scrutiny on weight loss differentiation
Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.
Kailera Therapeutics faces scrutiny on weight loss differentiation. Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.